Intellia Therapeutics (NTLA) Tops Q1 EPS by 10c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.81), $0.10 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $15.04 million versus the consensus estimate of $13.51 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings